AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment

Inclusion Criteria: * Stenotic (\> 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries * Length of lesion \< 20mm (less than one stent length) * Reference vessel diameter should be 3.0-3.5 mm * A maximum of two lesions in one infrapopliteal vessel treated within the study, or in two vessels of two different legs. (PTA treatment of other infrapopliteal lesions in non-study vessels is allowed outside the study). * Symptomatic critical limb ischemia (Rutherford 4, 5) * The patient must be ≥ 50 years. * Life-expectancy of more than 6 months * The subject or legal guardian has been informed of the nature of the study; agrees to its provisions and has signed informed consent * The patient must be available for the appropriate follow-up times for the duration of the study * The patient is capable to follow all study requirements. Exclusion Criteria: * Patient refusing treatment * The reference segment diameter is not suitable for available stent design * Length of lesion requires more than one stent implantation * Previously implanted stent(s) or PTA at the same lesion site * Lesion lies within or adjacent to an aneurysm * Inflow-limiting arterial lesions left untreated * The patient has a known allergy to heparin, Aspirin or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies. * The patient takes Phenprocoumon (Marcumar). * The patient has a history of prior life-threatening contrast media reaction. * The patient is currently enrolled in another investigational device or drug trial. * The patient is currently breast-feeding, pregnant or intends to become pregnant. * The patient is mentally ill or retarded. * The patient is liable for military or civilian service.